Synta Pharmaceuticals
Pharmaceuticals, 200 Barr-Harbor Dr, West Conshohocken, Pennsylvania, 19428, United States, 51-200 Employees
Phone Number: 78********
Who is SYNTA PHARMACEUTICALS
Synta Pharmaceuticals is an innovative, agile biopharmaceutical company focused on research, development and commercialization of novel oncology medicines that have the potential to chang...
Read More
-
Headquarters: 200 Barr-Harbor Dr, West Conshohocken, Pennsylvania, 19428, United States
-
Date Founded: 2000
-
Employees: 51-200
-
Revenue: $250 Million to $500 Million
-
Active Tech Stack: See technologies
Industry: Pharmaceuticals
SIC Code: 2834
|
NAICS Code: 325412 |
Show More
Does something look wrong? Fix it. | View contact records from SYNTA PHARMACEUTICALS
Synta Pharmaceuticals Org Chart and Mapping
Email
Phone
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding Synta Pharmaceuticals
Answer: Synta Pharmaceuticals's headquarters are located at 200 Barr-Harbor Dr, West Conshohocken, Pennsylvania, 19428, United States
Answer: Synta Pharmaceuticals's phone number is 78********
Answer: Synta Pharmaceuticals's official website is https://syntapharma.com
Answer: Synta Pharmaceuticals's revenue is $250 Million to $500 Million
Answer: Synta Pharmaceuticals's SIC: 2834
Answer: Synta Pharmaceuticals's NAICS: 325412
Answer: Synta Pharmaceuticals has 51-200 employees
Answer: Synta Pharmaceuticals is in Pharmaceuticals
Answer: Synta Pharmaceuticals contact info: Phone number: 78******** Website: https://syntapharma.com
Answer: Synta Pharmaceuticals is an innovative, agile biopharmaceutical company focused on research, development and commercialization of novel oncology medicines that have the potential to change the lives of cancer patients. Our lead oncology drug candidate, ganetespib, a novel heat shock protein 90 (Hsp90) inhibitor, is currently being evaluated in several large randomized clinical trials including GALAXY-2, a pivotal Phase 3 trial in non-small cell lung cancer (NSCLC), as well as in breast cancer, ovarian cancer and acute myeloid leukemia (AML). Ganetespib has been studied in approximately 1350 patients in clinical trials to date. In preclinical models, ganetespib inhibits a molecular chaperone called Hsp90, essential to the function of many of the most fundamental drivers of cancer cell growth and proliferation. Treatment with ganetespib has been shown in preclinical models to reduce some aggressive features of tumors, such as the ability to induce the growth of new blood vessels (angiogenesis), to spread to other organs in the body (metastasis), and to resist attack by traditional therapies (chemo-resistance). We are also developing several candidates from our proprietary Hsp90 inhibitor Drug Conjugate Program (HDC Program), which leverages the preferential accumulation of Hsp90 inhibitors in tumors to selectively deliver a wide array of anti-cancer payloads. Our first clinical candidate from our HDC Program, STA-12-8666, is undergoing testing to enable the filing of an investigational new drug application (IND). Preclinical evaluation of additional HDC candidates is ongoing.
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Get Full Access
Sign in to CIENCE GO Data to uncover contact details
Free credits every month